Intrexon is a gene expression and regulation company focused on control of cells and organisms that is headquartered in Germantown, Maryland and was founded in 1998. The company is developing technology for biological systems across four major biology classes - Microbes, Plants, Animals, Human Cells - to protect the environment, promote health, and feed the growing populations of humans and animals. The company is also developing gene and cell therapies using precision immunology. Intrexon is using several technologies to develop their products which give them the capability to precisely control gene expression, design and engineer biosystems, and engineering gene function and delivery.
On January 23, 2017 Intrexon acquired a gene therapy company called GenVec for approximately $15.9 million. The deal gave stockholders of GenVec 0.297 of an Intrexon share for each share of GenVec common stock based on Intrexon's five-day weighted average as of January 23, 2017.
Timeline
Funding rounds
People
Abhay Jain
Employee
Ali A. Faruqi
Employee
Amanda
Employee
Angeline Marie Puranen
Employee
Anissa N Elayadi
Employee
Anjan Aralihalli
Employee
Catharine Haak
Employee
Christopher McCarthy
Employee
Corey Huck
Employee
Darren Blanton
Investor
Darwin Sorento Dichmann
Employee
David Hunt/Hunt Technology Ventures, L.P.
Investor
David Nunn
Employee
David Pyrce
Investor
David R Bachinsky
Employee
David Simms
Employee
Di Wu
Employee
Ephie Ng
Employee
Jack A Bobo
Employee
James Brennan
Employee
James Kerrigan
Employee
Jason Avant
Employee
Johan A Kers
Employee
John Beaber
Employee
Kyle DiFiore
Investor